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SUMMARY. Worldwide, the hepatitis B virus (HBV) and the
hepatitis C virus (HCV) cause, respectively, 600 000 and
350 000 deaths each year. Viral hepatitis is the leading
cause of cirrhosis and liver cancer, which in turn ranks as
the third cause of cancer death worldwide. Within the WHO
European region, approximately 14 million people are
chronically infected with HBV, and nine million people are
chronically infected with HCV. Lack of reliable epidemio-
logical data on HBV and HCV is one of the biggest hurdles to
advancing policy. Risk groups such as migrants and inject-
ing drug users (IDU) tend to be under-represented in existing
prevalence studies; thus, targeted surveillance is urgently
needed to correctly estimate the burden of HBV and HCV.
The most effective means of prevention against HBV is
vaccination, and most European Union (EU) countries have
universal vaccination programmes. For both HBV and HCV,
screening of individuals who present a high risk of
contracting the virus is critical given the asymptomatic, and
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thereby silent, nature of disease. Screening of migrants and
IDUs has been shown to be effective and potentially cost-
effective. There have been significant advances in the
treatment of HCV and HBV in recent years, but health care
professionals remain poorly aware of treatment options.
Greater professional training is needed on the management
of hepatitis including the treatment of liver cancer to
encourage adherence to guidelines and offer patients the best
possible outcomes. Viral hepatitis knows no borders. EU
Member States, guided by the EU, need to work in a con-
certed manner to implement lasting, effective policies and
programmes and make tackling viral hepatitis a public
health priority.
Keywords: Europe, hepatitis B, hepatitis C, liver cancer,
policy.
INTRODUCTION
Hepatitis B (HBV) and C (HCV) virus infections constitute a
major global public health threat. About 2 billion people
have been infected with HBV, of whom 350 000 are
chronically infected. Between 130 and 170 million people
are chronically infected with HCV worldwide. Approximately
600 000 and 350 000 deaths each year occur as a result of
HBV and HCV infections, respectively [1]. Chronic hepatitis
B and C are leading causes of cirrhosis and hepatocellular
carcinoma (HCC), which ranks as the third cause of cancer
deaths worldwide. Globally, 2.7% of all deaths are because of
liver cancer and cirrhosis resulting from HBV and HCV, and
this percentage is increasing over time. Hepatitis B is
thought to be 50–100 times and hepatitis C up to 10 times
more infectious than human immunodeficiency virus (HIV)
[2,3].
In Europe, the threat posed by chronic viral hepatitis is
becoming more apparent. Within the World Health Orga-
nisation (WHO) European region, about 14 million people
are chronically infected with hepatitis B, and nine million
people are chronically infected with hepatitis C, in compar-
ison with 1.5 million infected by HIV. Thirty-six thousand
people die each year because of HBV-related causes and
86 000 because of HCV (N. Emiroglou, WHO data presented
at Hepatitis B and C Summit Conference, October 2010).
Despite these staggering figures, there is little under-
standing at the public or policy level of the health implica-
tions of hepatitis B and C in the European Union (EU) or
elsewhere (see Panel 1). Surveys conducted by the European
Liver Patients Association (ELPA) suggest that up to 90% of
infected people in the EU are unaware of their condition.
Among diagnosed individuals, 20% said they had never
heard of viral hepatitis at the time of their diagnosis, and
27% did not know that they were at high risk of transmitting
the infection [4]. Similar figures were reported by the Insti-
tute of Medicine [5] report in the United States, which stated
that 65% of those infected with HBV and 75% of those
infected with HCV admitted that they were unaware of their
condition. Lack of awareness on the part of health care and
social service providers might partly explain why both HBV
and HCV are generally under-diagnosed and under-treated.
At the policy level, viral hepatitis is often not recognized as a
serious but treatable public health problem, and therefore,
the resources allocated towards its prevention and man-
PANEL 1: SUMMARY FINDINGS OF THE
INSTITUTE OF MEDICINE REPORT
In 2010, the US Centres for Disease Control and Pre-
vention (CDC), along with the Department of Health and
Human Services and other federal bodies, asked the
Institute of Medicine to identify missed opportunities
related to the prevention and control of HBV and HCV
infections. The ensuing report has relevance far beyond
the US context. Summary findings and recommendations
are summarized below:
Factors that impede current efforts to prevent and
control hepatitis B and hepatitis C are as follows:
• There is a lack of knowledge and awareness about
chronic viral hepatitis on the part of health care and
social service providers
• There is a lack of knowledge and awareness about
chronic viral hepatitis among at-risk populations,
members of the public and policymakers
• There is insufficient understanding about the extent
and seriousness of this public health problem, so
inadequate public resources are being allocated to
prevention, control and surveillance programmes.
The consequences of this situation are as follows:
• Inadequate disease surveillance systems underreport
acute and chronic infections, so the full extent of the
problem is unknown.
• At-risk people do not know that they are at risk or
how to prevent becoming infected.
• At-risk people may not have access to preventive
services.
• Chronically infected people do not know that they are
infected.
• Many health care providers do not screen people for
risk factors or do not know how to manage infected
people.
• Infected people often have inadequate access to
testing, social support and medical management
services.
• There is suboptimal coverage of HBV vaccination.
Adapted from [5].
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agement are largely insufficient. The EU still lacks a unified
comprehensive strategy to tackle viral hepatitis, and many
EU Member States have done relatively little to establish
robust viral hepatitis policies and programmes.
The hepatitis B and C summit conference
It is against this background that the hepatitis B and hepa-
titis C Conference was created. The Conference involved a
wide range of stakeholders in a vigorous partnership whose
goal is to curtail the growing and evolving impact of hepa-
titis B and C in Europe through effective polices and targeted
actions.
The Conference held its first summit on 14–15 October
2010 bringing together expert clinicians, public health
specialists, patient groups, EU and national policymakers.
This paper presents the main findings and conclusions
drawn from the conference and includes the Call to Action
for the EU and Member States on hepatitis B and C. Con-
ference presentations and background documents may be




Mandatory surveillance of both hepatitis B and C is common
across all of Europe, and a common data set is collected in
most Member States. However, there is great heterogeneity
in surveillance protocols in terms of case definitions used.
Most surveillance focusses on acute, usually symptomatic,
cases or, in the case of HBV, does not distinguish between
acute and chronic cases. There is little possibility for linking
existing registries because of the lack of an established
network, such as exists in the case of HIV/acquired immu-
nodeficiency syndrome (AIDS). Available data on hepatitis C
in particular may be more a reflection of existing screening
practices and laboratory test data rather than actual epide-
miological surveillance. In light of these deficits, the Euro-
pean Centre for Disease Prevention and Control (ECDC)
included hepatitis B and C in its enhanced surveillance
programme as of 2010, in the hope of greatly improving the
quality and reliability of epidemiological data on hepatitis B
and C in Europe [6].
Prevalence of hepatitis B and C
The prevalence of chronic HBV infection in the general
population ranges from 0.2% in Ireland and the Netherlands
to over 7% in some parts of Turkey. The prevalence of HCV
also varies from 0.4% in Sweden, Germany and the Neth-
erlands to over 2–3% in some Mediterranean countries.
High-risk, vulnerable groups such as IDUs, migrants,
homeless persons and prisoners tend to be under-represented
in general population studies, so that prevalence figures for
these populations are likely to be considerably underesti-
mated, especially in low-prevalence countries [7].
Complications
The natural history of chronic hepatitis B is complex and
highly variable. The incidence of cirrhosis is 0.1% per year in
inactive carriers of hepatitis B surface antigen (HBsAg) and
2–10% per year in individuals with chronic hepatitis B. The
5-year cumulative risk of developing HCC in cirrhotic
patients varies by region: it is 17% in East Asia and 10% in
Europe and USA. The 5-year liver-related death rate in
cirrhotics is 15% [8]. The risk of complications depends on
factors, such as gender, age, severity of liver disease,
co-infections [such as hepatitis D virus (HDV), HCV and
HIV], HBV replication status and external factors such as
alcohol intake, smoking and environmental carcinogens
(such as aflatoxins) [9]. Serum HBV-DNA level is a direct
measure of HBV replication and a major predictor of
cirrhosis and HCC. Other independent predictors of cirrhosis
are male sex, older age, hepatitis B e antigen positivity and
elevated alanine aminotransferase (ALT) [10,11].
The natural history of chronic hepatitis C is also highly
variable (Table 1). The progression of chronic hepatitis C is
related to nonmodifiable factors, such as age at infection,
sex, race, and host genetics, and potentially modifiable fac-
tors such as ALT levels, alcohol consumption, uncontrolled
co-infections (HIV, HBV, schistosomiasis), cigarette smoking,
cannabis use, iron overload, liver steatosis and insulin
resistance [12,13].
Both hepatitis B and C are associated with excess mor-
tality. In a recent study that examined all diagnoses of
HCV made in Scotland between 1991 and 2006, HCV-
infected individuals had a higher all-cause and a higher
liver-related mortality rate compared to the general popu-
lation, even after allowing for deprivation [standardized
mortality rate (SMR) for overall mortality 3.41 (95% CI
3.3–3.5), for liver-related diagnoses SMR 41.3, 95% CI
39.6–43.0] [14].
Primary liver cancer (HCC)
The heavy toll of HCC in Europe has only become clear over
the past 10–15 years. In Europe, 60–70% of HCC cases are
caused by HCV, 10–15% by HBV, 20% by alcohol and 10%
by other causes [15–17]. The relative importance of different
risk factors varies by region (Table 2). Cirrhosis remains the
greatest risk factor for HCC: the risk of HCC is 15–20% in
cirrhotic patients, and the number of cirrhosis cases is
increasing in Europe [9,18,19]. The incidence and risk of
death attributed to liver cancer appear to be highest in
Southern Europe for both men and women. However, dif-
ferences between countries may reflect different screening
and testing practices rather than actual epidemiology.
 2011 Blackwell Publishing Ltd
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VACCINATION AGAINST HEPATITIS B
Universal vaccination against hepatitis B has been advocated
by the WHO since 1991, and 177 countries have currently
implemented universal vaccination programmes worldwide
with an outstanding record of safety and efficacy. Vaccina-
tion has been clearly shown to reduce the incidence, carrier
rates and mortality related to hepatitis B. Taiwan is perhaps
the best example of a previously highly endemic area, which
has shown a substantial decrease in the burden of hepatitis B
and HBV-related diseases following the introduction of mass
vaccination of newborns in 1984. The annual average
incidence of HCC among children declined significantly after
the implementation of vaccination in Taiwan, demonstrat-
ing clearly that hepatitis B vaccine is the first vaccine that
can prevent a major human cancer [20]. Likewise, in other
previously endemic areas (for example, the Gambia, Malay-
sia and Alaska), vaccination has proven to be very suc-
cessful.
Within the European region, most countries offer uni-
versal vaccination. However, the UK and Scandinavian
countries still do not advocate universal vaccination and
have opted on economic grounds for targeted vaccination
focussed on well-defined risk groups. Surveillance data from
Italy, where universal vaccination started in 1991 in infants
as well as in adolescents, have shown a remarkable overall
decline in incidence of acute hepatitis B after the imple-
mentation of vaccination [21] (Fig. 1). Moreover, a gener-
ation of children and young adults (at present aged <32) is
emerging with practically no markers for HBV infection. In
addition, because of the virological association between HBV
and HDV, an added benefit of vaccination is that the decline
in incidence of hepatitis B has caused a parallel decline in
hepatitis D.
Subclinical infections characterized by the appearance of
anti-HBc antibody or transient elevations of ALT have been
occasionally observed in successfully vaccinated people.
Infections caused by HBV S-gene mutants, including the
prototype glycine to arginine substitution (G145R), have
been observed in several countries, particularly Taiwan.
Despite the initial concern that these mutants could evade
the vaccine-induced immune response and infect vaccinated
individuals, at present, they are not known to pose a public
health threat [21]. A number of case reports from France in
1998 and thereafter raised concern that hepatitis B vacci-
nation may lead to new cases or relapses of neurological
Table 1 Natural history of hepatitis C from retrospective,
prospective and retrospective–prospective cohort studies
(modified from [12])
Retrospective Studies
Intervals from exposure 9–29 years




Intervals from exposure 8–16 years







Exposure interval 9–45 years










Table 2 Risk factors for hepatocellular carcinoma (HCC)





B virus Alcohol Other
Europe 60–70 10–15 20 10
North America 50–60 20 20 10
Asia* and Africa 20 70 10 <10
*Except Japan, where HCV accounts for 70%, HBV for 10–
20%, alcohol for 10% and others <10% of cases.
Aflatoxin is main co-factor enhancing oncogenetic risk of


































































Source: Sistema Epidemiologico Integrato Epatiti Virali Acute (SEIEVA), Rome
Fig. 1 Morbidity rate (·105 inhabitants) of hepatitis B in
Italy, according to age (1990–2009).
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diseases; however, no clear causal link has been established
[22–24].
Evidence indicates that vaccine-induced hepatitis B sur-
face antibodies (anti-HBs) are long lasting and may persist
for over 15 years. Vaccinees who have lost protective
(<10 mIU/mL) anti-HBs antibody usually show a rapid
anamnestic response when boosted [25]. This means that
immunological memory for HBsAg can outlast antibody
detection, providing long-term protection against HBV
infection and the development of the carrier state [26].
Hence, for immunocompetent individuals, booster doses of
vaccine do not seem necessary to ensure long-term protec-
tion [27–29].
Globally, remarkable progress in the introduction and
implementation of vaccination against hepatitis B has been
achieved in recent years, but much remains to be done to
meet the WHO goal of controlling hepatitis B in the com-
munity at large. At present, most countries not yet covered
by vaccination are those of low economic status and high
endemicity. Thus, efforts are urgently required to override
the economic barriers that hamper both the standard of
living and the implementation of universal vaccination
policies in such countries. In addition, extensive migration
and travel to and from highly endemic countries may
increase the risk of exposure to the virus, thereby necessi-
tating a global strategy for the control of HBV infection.
Based on the positive impact of hepatitis B vaccination,
support for further development of hepatitis C vaccine
research has been expressed.
HBV AND HCV SCREENING
Close to three-quarters of people infected with HCV or HBV
are unaware of their condition; thus, screening of high-risk
populations is paramount if one is to identify infected
individuals and offer them appropriate management [4,5].
Targets for screening vary from one programme to another
and may include blood, tissue and organ donors, pregnant
women, health care workers, IDUs, men who have sex with
men, sex workers, subjects with promiscuous sexual behav-
iour and migrants from high-prevalence areas. Ideally, all
subjects with symptoms and signs of liver disease, including
those with elevated serum aminotransferases, as well as
household and sexual contacts of HBV- or HCV-positive sub-
jects should be screened for HBV and HCV, as appropriate.
Moreover, all individuals with positive HBsAg should be
screened for hepatitis delta virus, given that chronic hepatitis
delta is the most aggressive form of viral hepatitis.
In its most recent report on viral hepatitis, the ECDC
conducted a review of screening practices and studies in
Europe [7]. The report reveals striking heterogeneity in
screening practices across the EU. For example, a number of
countries still do not offer hepatitis screening to pregnant
women, thereby forfeiting the critical opportunity to prevent
mother-to-child transmission. Screening among blood
donors is, by contrast, systematically undertaken across the
EU. There is a general lack of information on the cost-
effectiveness of screening high-risk groups for viral hepatitis.
Only two studies were identified, and both suggested that
screening of migrant groups for HBV and HCV was both
clinically effective and cost-effective [30,31]. The evidence
supporting screening for IDUs is somewhat more favourable,
particularly for HCV. However, implementation of screening
policies and uptake of screening among IDUs is reported to
be very low and fragmented as many drug treatment centres
do not offer screening on a routine basis [7]. The limited
evidence for cost-effectiveness does not imply that screening
is not likely to be cost-effective but that for most high-risk
groups where screening might be highly cost-effective, the
number of studies is limited [32].
Within the EU, screening programmes are very limited
[33], and only France and Scotland have instituted a gov-
ernment-led programme to improve screening of high-risk
groups in a sustainable and comprehensive manner. The
Scottish programme focusses solely on HCV. The Nether-
lands has conducted a number of pilot projects offering
screening against HBV to Chinese communities. Targeted
screening campaigns have also been very successful in other
countries, such as the Silesia region in Poland and the
Blackpool in England, where mortality rates from chronic
liver disease are very high. Some of the main lessons learned
from some of these screening programmes are presented in
Panel 2.
The Institute of Medicine Report on Hepatitis and Liver
Cancer in the USA has recently formulated five core
functions for comprehensive hepatitis services: (i) commu-
nity outreach, (ii) prevention, (iii) identification of infected
persons, (iv) social and peer support and (v) medical
support. Identification of infected persons is a two-step
process: (i) risk factor screening and (ii) serological testing
for HBV and HCV [5]. A summary of updated recommen-
dations on screening of high-risk populations for hepatitis B
and C from the US Centres for Disease Control (CDC) is
shown in Table 3.
TREATMENT
There have been considerable advances in the antiviral
treatment of hepatitis B and C over the past decade, such
that today viral replication can be effectively suppressed in
95% of cases of chronic hepatitis B and 60% of chronic
hepatitis C cases can be cured [34–37]. There is also growing
evidence suggesting that treatment options for hepatitis B
and C are cost-effective and form part of the control of the
disease [38].
Hepatitis B
Hepatitis B has often been termed a silent killer as patients
often remain asymptomatic – and thereby undiagnosed – for
 2011 Blackwell Publishing Ltd
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several years and even decades. Even once diagnosis is made,
active treatment rates remain very low, despite cumulative
evidence that early treatment and viral suppression greatly
reduce the risk of progression to cirrhosis, liver cancer and
eventual death [8,36].
Treatment is usually focussed on the immune-active
phases of disease when rates of progressive fibrosis are
increased. The goals of treatment for hepatitis B are to pre-
vent cirrhosis, hepatic decompensation and HCC and thereby
to improve mortality rates and quality of life by preventing
progression of the disease [39]. The two possible treatment
approaches include either stimulating the immune system
(through pegylated interferon) or suppressing viral load
through nucleo(t)side analogues. An illustration of treat-
ment options is presented in Fig. 2. Most recent research
efforts have focussed on nucleo(t)side analogues. Given that
patients may be receiving treatment for an extended period
of time, potent and safe agents with a low rate of resistance
are favoured. The most recently available agents for hepatitis
B (tenofovir and entecavir) show promising resistance pro-
files; however, patient adherence remains challenging,
especially during asymptomatic phases of the disease.
Combination with pegylated interferon should be further
evaluated to assess the possibility of finite or reduced dura-
tion treatment regimens.
PANEL 2: CONSIDERATIONS FOR THE
IMPLEMENTATION OF SUCCESSFUL
SCREENING PROGRAMMES FOR HBV AND
HCV
• Develop clear public awareness campaigns targeted at
the general public and at risk groups.
• Need a clear clinical strategy to deal with HBV- and
HCV-infected persons.
• Revise clinical guidelines to endorse HBV and HCV
screening in specified risk groups and reinforce dis-
semination of best practices for case finding.
• Integrate screening into existing public health and
care practices whenever possible.
• Conduct HBV & HCV screening in HIV/STD clinics,
prisons, drug user services as well as in primary care
clinics.
• Simplify screening criteria, e.g. adopt age-based
criteria for HCV, birth place for HBV with the aim
of providing clear guidance to GPs and those
screening patients.
• Educate providers about the needs for screening and
about the management pathways for HBV- and HCV-
infected individuals.
• Always carry out screening in an evidence-based
way that defines when and how often screening
should be offered and respects the human rights of
those screened.
• Always accompany screening with appropriate coun-
selling of the individual and his or her family.
• In the case of marginalized or stigmatized groups such
as migrants or IDUs, one must ensure that individuals
are not stigmatized because of their group member-
ship or their viral hepatitis status.
Table 3 Updated summary of Centres for Disease Control
recommendations for high-risk populations for hepatitis B
and hepatitis C (adapted from [5])
Hepatitis B
Persons born in geographic regions that have
hepatitis B surface antigen prevalence of at least 2%
Infants born to infected mothers
Household contacts of persons who have
chronic HBV infection
Sex partners of infected persons
Injection-drug users
Sexually active persons who are not in long-term,
mutually monogamous relationships (for example,
more than one sex partner during previous
6 months)
Men who have sex with men
Health care and public safety workers at risk for
occupational exposure to blood or
blood-contaminated body fluids
Residents and staff of facilities for developmentally
disabled persons
Persons who have chronic liver disease
Haemodialysis patients
Travellers to countries that have intermediate or high
prevalence of HBV infection
Hepatitis C
Persons who have ever injected illegal drugs, including
those who injected only once many years ago
Recipients of clotting factor concentrates made
before 1987
Recipients of blood transfusions or solid-organ
transplants before July 1992
Patients who have ever received long-term
haemodialysis treatment
Persons who have known exposures to HCV, such as
Health care workers after needlesticks involving
HCV-positive blood
Recipients of blood or organs from donors who later
tested HCV positive
All persons who have HIV infection
Patients who have signs or symptoms of liver disease
(for example, abnormal liver enzyme tests)
Children born to HCV-positive mothers (to avoid
detecting maternal antibody, these children should
not be tested before the age of 18 months)
 2011 Blackwell Publishing Ltd
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Hepatitis C
With appropriate treatment, clearance of circulating HCV
RNA or a sustained virological response (SVR) that is con-
sidered tantamount to a cure of chronic hepatitis C can be
achieved in up to 60% of cases, effectively resulting in a
reversal of the natural history of the disease [40,41]. Cur-
rently, combination therapy using pegylated interferon and
ribavirin is the most widely used treatment option. Side
effects include neutropenia, anaemia and depressive or other
mood changes. The search for improved cure rates is being
actively pursued, and tailored treatment algorithms based on
the kinetics of response to treatment and genetic variations
of the host are being developed [40,41]. Several new
therapeutic options, using direct antiviral agents including,
for example, first-generation protease inhibitors (boceprevir,
telaprevir) in combination with pegylated interferon and
ribavirin, have completed phase 3 clinical trials for patients
infected with HCV genotype 1 and have recently been
approved for use in the United States and are awaiting
imminent approval in Europe. These new regimens improve
the efficacy of treatment in genotype 1 HCV. A large number
of second-generation protease inhibitors, polymerase
inhibitors, nonstructural protein 5a inhibitors as well as
host-acting antiviral agents are currently in phase 2 and 3
assessment.
Treatment of advanced disease
The treatment of advanced liver disease, including liver
cancer, has been transformed in the past 20 years. Several
studies have provided histological evidence that cirrhosis can
in part be reversed in patients infected with HBV and HCV
[36,42]. Twenty-five years ago, liver cancer was thought to
be incurable. Yet today, multiple treatment options exist,
such as treatment with surgical resection, liver transplan-
tation, percutaneous ablation, transarterial chemoemboli-
zation and sorafenib, which have demonstrated improved
survival in patients with liver cancer [43,44]. Physicians
outside of specialist centres need to be better informed about
treatment options for patients with liver cancer and made
aware of existing guidelines for the surveillance and man-
agement of liver cancer to ensure that they guide their pa-
tients towards appropriate care [44,45].
VULNERABLE POPULATIONS
Migrants
Despite the fact that a large proportion of migrants into the
EU come from countries of high endemicity for HBV and
HCV, the topic of viral hepatitis and migration has received
little attention thus far [46].
Prevalence rates of HBV and HCV obtained from migrants
are much higher than those obtained from general popula-
tion surveys – in which migrants tend to be under-repre-
sented. For example, a German study estimated that there
were approximately half a million HBV carriers in Germany
in 2005, of whom individuals from a migrant background
accounted for 43%, when they only make up 13% of the
general population [47].
Migrants may face several barriers to prevention and care
that need to be acknowledged in all policies and programmes
for hepatitis B and C. Poverty, distance and poor
transportation, limited access to care, literacy rates, levels of
parental education (in the case of children) and cultural,
linguistic and religious differences or administrative rules
may all act as barriers for migrants to access vaccination,
screening and other hepatitis services [48,49].
Illegal migrants present particular challenges as they are
not acknowledged by (or known to) public health authorities
and they are largely inaccessible to health initiatives. As was
suggested in a special report commissioned for the Confer-
ence on the topic of migration and viral hepatitis, the con-
ditions of life, marginalization from health care systems and
reluctance/fear of being identified by judicial authorities
make the task of reaching illegal migrants with screening,
early diagnosis and treatment difficult [46].
The diversity of needs among migrant communities must
be taken into account in all policies and programmes to
ensure that actions are culturally sensitive and appropriate.
We need to gain a better understanding of the prevalence,
disease burden and barriers to care faced by migrant com-
munities across Europe to ensure that the burden of hepatitis
B and C is reduced within this vulnerable population [46].
Injecting drug users
Injecting drug users constitute a large proportion (40%) of
notified acute cases of hepatitis C, suggesting that currently
they are a very important risk group for new infections [50].
In the EU, HCV is far more prevalent than HBV or HIV
among IDUs and often reaches extremely high levels. Data
from seroprevalence studies routinely collected by the











Fig. 2 Treatment options for hepatitis B.
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(EMCDDA) suggest that the prevalence of serological mark-
ers for HBV and HCV is much higher in IDUs than in the
general population. However, general notification data on
hepatitis B and C are very poor, with levels of under-diag-
nosis and under-reporting that may reach up to 50–98%
[51,52]. Therefore, despite having their own limitations,
seroprevalence studies specifically targeted at IDUs and other
risk groups are important.
Guidelines for testing IDUs for HIV, viral hepatitis and
other infections have recently been published by the
EMCDDA [52]. Evidence suggests that treatment of active
IDUs with antiviral therapy may be one of the best ways to
contain the burden of HCV, contrary to existing guidelines
that often discourage treating active injectors. A recent
modelling study suggests that, based on realistic treatment
capacity, treating 40 per 1000 IDUs annually could result in
a 70% decrease in HCV prevalence over a 10-year period
[53]. The underlying principle of this treatment for pre-
vention approach, also advocated by the HIV/AIDS research
community, is that the overall viral load in the population
can be reduced through effective treatment of those infected,
thereby halting the cycle of transmission [54]. In the case of
hepatitis C, sustained viral responses (SVR) in this
population pool would result in reduced transmission rates.
Currently, <1% of the population of IDUs in the UK is
thought to receive active treatment. Data are not available
from other countries. The main reason for such low treat-
ment rates is ongoing concern over the safety of interferon in
active drug users, potential non-compliance with treatment
and risk of re-infection because of ongoing drug use and co-
existing psychiatric disorders. A number of studies, however,
have found that these problems can be addressed [55,56].
THE STATE OF POLICY
Important strides have been made to raise the profile of
hepatitis on the policy agenda in recent years. In May 2010,
the World Health Assembly adopted the 63rd World Health
Assembly Resolution on Viral Hepatitis. The WHO is
adopting a regional strategy for viral hepatitis for the entire
European region focussing on three pillars:
• immunization of newborns and high-risk groups against
hepatitis B,
• integration of hepatitis prevention and care into
nationalpublichealthprogrammesandinterventions,and
• safe health care services to prevent blood-borne infec-
tions (N. Emiroglou, conference presentation).
Hepatitis is also gaining visibility at the EU level. The ECDC
included hepatitis B and C in its enhanced surveillance
programme in 2011, which promises to greatly improve the
evidence base that can underpin the development of targeted
programmes and actions. The EMCDDA is annually collect-
ing and reporting data on HCV and HBV seroprevalence in
IDUs. The European Commission may also play an important
role in guiding hepatitis policy, through its public health and
research programmes. The Directorate General for Health
and Consumers (DG-Sanco) has funded several projects
targeting hepatitis, a full list of which can be found on
http://ec.europea.eu/eahc/index.html. DG Research unfor-
tunately has provided very limited support to hepatitis
research through its Framework Programme so far. It has
engaged in a vaccine effort, HEPCIVAC, which is focussed on
finding new preventative and therapeutic HCV vaccines, as
well as developing HCV disease predictive biomarkers. In
HBV, the focus has been only on HIV–HBV co-infection. And
finally, the European Medicines Authority (EMA) has drafted
guidance to drug developers on the clinical evaluation of
antiviral agents against HBV and HCV [57,58].
Yet, despite these efforts, much work remains to be carried
out. An EU Council Resolution on hepatitis B and C is
urgently needed. The EU is still characterized by a lack of
standardized policies and practices. For example, antenatal
screening against hepatitis B and C should be offered to all
pregnant women to help prevent mother-to-child transmis-
sion of the virus. Whilst it may be argued that the diverse
epidemiology of hepatitis B and C warrants policies and
programmes tailored to each national epidemiological situ-
ation, it should be emphasized that, from an EU public health
perspective, managing diversity should not mean tolerating
unjustified inequalities (see address by Dr Marc Sprenger,
Annex I).
The EU may play a leadership role in public health.
However, plans to tackle HBV and HCV must be developed
and implemented at the national level. Countries seeking to
develop programmes targeting hepatitis B and C may draw
lessons from successful initiatives from within and outside
the EU which have achieved encouraging results. Some
examples of national programmes presented at the Confer-
ence are presented in Panels 3 & 4. Finally, it is at the
national level that the resources to implement policies and
programmes targeting hepatitis B and C are deployed. A
recent report published by the Institute of Medicine [5] in the
United States pointed to huge gaps in policy and resources
devoted to tackling hepatitis B and C and concluded that,
despite its significant toll in terms of public health, neither
HBV nor HCV receives adequate funding compared to other
communicable diseases such as HIV/AIDS. Similar conclu-
sions may be drawn for Europe and point to the urgent need
to appropriately allocate funds and resources targeted
towards the control and management of viral hepatitis.
Nowadays, in most European countries, many more people
are dying from the complications of viral hepatitis than from
AIDS. Comparative figures for viral hepatitis and HIV
regarding awareness and funding from the United States,
presented during the conference, are shown in Table 4.
It is against this background that the Conference Summit
launched its Call to Action to all policymakers and stake-
holders concerned with hepatitis B and C in the EU (Annex
II). The EU has a clear mandate in communicable diseases. A
Council Recommendation on viral hepatitis will help guide
 2011 Blackwell Publishing Ltd
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national action. The message to be communicated to EU
institutions is that current figures underestimate the true toll
of hepatitis B and C and that urgent actions need to be taken
at all levels. In particular, more prominence for hepatitis B
and C should be sought within public health and research
programmes in the next wave of European Commission
funding.
CONCLUSIONS
The main conclusions from the Conference can thus be
summarized as follows:
Enhanced surveillance of hepatitis B and C is urgently
needed
One of the biggest gaps in the advancement of policy on viral
hepatitis is the lack of reliable data on the epidemiology of
both hepatitis B and C across Europe. There is an urgent
need for extensive surveillance networks, for a common
protocol for prevalence studies and for improved and more
representative epidemiological data overall on both hepatitis
B and C.
Vaccination remains the most effective preventive approach
against HBV
Within the European region, most countries offer universal
vaccination, yet within the EU, seven countries still do not
have universal vaccination and have opted instead for tar-
PANEL 3: KEY FACTORS NECESSARY FOR THE
SUCCESSFUL IMPLEMENTATION OF
PREVENTION AND MANAGEMENT
PROGRAMMES TARGETING HBV AND/OR
HCV
• Reliable local epidemiological data to communicate
with policymakers
• Clinical leadership from specialist centres as well as
from public health, social services and other relevant
professional groups
• Motivation of all those involved in programme
using quantifiable goals (e.g. 75% of patients
with HepC will be aware of their infection by a given
year)
• Inclusion of concrete goals to extend treat-
ment in line with existing – and desired – treatment
capacity
• Recognition of the need for and potential of thera-
peutic developments to confer true patient benefits
• Strong, continuous patient advocacy
• Close and ongoing dialogue between patients, clinical
leads, public health specialists and policymakers
• Awareness campaigns to increase testing through GPs
and other primary care providers
• Systematic referral system for individuals screening
positive to secondary care
• Targeted awareness campaigns (e.g. aimed at different
immigrant communities)
• Strengthening of network between hospitals, GPs and
physicians in special settings (e.g. prisons or sexual
health clinics)
• Shared patient management between specialists and
GPs to lessen the burden on hospitals.
PANEL 4: THE SCOTTISH AND FRENCH
NATIONAL PLANS FOR HEPATITIS
French National Plan for Hepatitis B and C [59]
Achievements:
• Increase in proportion of patients aware of HCV
positivity from 24% to 56% (1994–2004) [59]
• Highest treatment rate for HepC in Europe (16% in
2005) [60]
• Demonstrated impact on morbidity and mortality
• Surveillance system implemented as part of National
Public Health Plan
Lessons learned:
• Migrants can be reached with outreach campaigns
• Ensure referral to secondary care
• HCV campaigns can increase testing through GPs
• Ensure referral to secondary care
• Motivation of quantifiable goals, e.g. 65% of patients
with HepB aware of their infection (HepC: 75%)
• Need to strengthen network between hospitals, GPs
and physicians in special settings
Scottish National Hepatitis C Plan
Achievements:
• Managed Care Networks for HepC
• National procurement of antivirals at reduced prices
• Increase in numbers diagnosed, doubling of numbers
treated
• Fivefold increase in number of prisoners treated
• New approaches for gauging incidence in IDUs
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geted vaccination of at-risk population. The justification for
the decision not to offer universal vaccination can be chal-
lenged. The coverage of HBV vaccination is low compared to
other childhood vaccines and needs to be improved. So, in
addition, universal vaccination should be complemented
with targeted vaccination of at-risk groups.
More resources must be devoted to screening programmes
for risk groups
Vulnerable and risk groups, particularly migrants and
IDUs, are under-represented in general population preva-
lence studies, and active targeted surveillance of these
populations is needed to correct existing prevalence esti-
mates. Screening of individuals who are at high risk of
having or contracting HBV or HCV is also critical to offer
early treatment and prevent carriers from infecting others.
Data from the ECDC and other studies suggest that
screening of certain risk groups is effective and potentially
cost-effective. Screening programmes must always be
accompanied by counselling, integrated into existing public
health and care practices and connected to treatment
programmes to be effective.
Early diagnosis and treatment are essential for both
hepatitis B and C
The message that, with treatment, 95% of chronic HBV
cases can be effectively treated by current antiviral agents,
thereby improving survival, and that 60% of chronic HCV
cases can be cured, reversing the natural history, must be
delivered clearly to all treating physicians, as well as poli-
cymakers and patients themselves. Extending treatment to a
greater number of patients not only improves the outcomes
but also reduces mortality for those treated, and it has
demonstrable public health impact as it reduces infectivity
and therefore transmission of HBV and HCV.
The importance of HCC in Europe should be recognized
Liver cancer is the third most important cancer in terms of
mortality and the sixth in incidence worldwide. In Europe,
data from several countries suggest that mortality from liver
cancer is rising. Greater efforts are needed to make the
medical community aware of the natural history of liver
cancer and its links to HCV and HBV, to improve adherence
to treatment guidelines and to convey the importance of
screening in HBV and HCV patients to diagnose HCC earlier
to improve survival and offer patients the best possible out-
comes. Mortality statistics should also include infection sta-
tus by HBV or HCV.
Successful national and local initiatives provide best
practice examples from which important lessons may be
learned
It is important to acknowledge that a number of national
and local programmes have achieved significant results in
curtailing the toll posed by HBV and HCV (see http://
www.hepsummit2010.org). Some key lessons derived from
these initiatives are that evidence-based and reliable epide-
miological data are essential to drive policy, that targeted
actions in migrants are effective, that treatment of active
IDUs has been shown to be effective and that quantifiable
goal, provide important motivation for success.
Patient advocacy groups play a critical role in advancing
policy and patient care
Despite chronic shortages of funds and low resources, patient
groups provide strong leadership in raising awareness of
hepatitis B and C in Europe. They also fill a critical gap by
raising awareness and in some cases offering counselling
and psychological support to patients that is usually missing
from traditional medical centres. The biggest hurdle faced by
patient groups, apart from funding shortages, is the low level
of interest or awareness among general practitioners, which
in turn limits the opportunities for increasing screening and
diagnosis of individuals infected with either HBV or HCV.
More initiatives that help engage general practitioners in
improving the prevention, screening and care of hepatitis B
and C are urgently needed.
Europe must recognize the importance of viral hepatitis
and make resources available to deliver policies
To quote MEP Alojz Peterle in his address to the Summit
Conference, the need for additional data must not be an
excuse for delaying policy action and recognising the
Table 4 Allocation of research funds towards HCV, HBV and
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important health threat viral hepatitis represents to Europe.
Even more so, since there is evidence that the burden will
increase in years to come. There have been important
strides made to this end in Europe. However, much still
needs to be done and we will only reach our goals if more
funds and resources are specifically allocated, both at EU and
national level, to make the fight against viral hepatitis a
priority as it deserves to be.
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ANNEX I: CONFERENCE ADDRESS BY DR MARC
SPRENGER, DIRECTOR OF THE EUROPEAN
CENTRE FOR DISEASE PREVENTION AND
CONTROL (ECDC)
Summary of Address: Dr Marc Sprenger, Director, European
Centre for Disease Prevention and Control: The ECDC View
I. Hepatitis B and C are serious public health problems
Hepatitis B and C are serious public health problems. Every
year, upwards of 7000 newly diagnosed cases of hepatitis B
and more than 27 000 newly diagnosed cases of hepatitis C
are reported in the EU. Many of these people go on to develop
liver cancer or liver cirrhosis, as a result of these infections.
Indeed, the World Health Organisation (WHO) estimates
that almost 80% of primary liver cancer cases are linked to
this viral hepatitis.
II. We have enough evidence to know that we must act
Here, then, you have viruses that are a leading cause of one
of the most common types of cancer in Europe. This defies
the distinction that health policymakers like to make be-
tween infectious and noncommunicable diseases. They often
argue that noncommunicable diseases are much more
important than communicable diseases, but we should be
careful if we consider hepatitis B and C as infectious diseases.
In a way they are, but the consequences are in a chronic
disease. It also makes estimating the number of deaths
attributable to hepatitis very complex. Nonetheless, I stress
that we have enough evidence already to know that we need
to do something. More research is always necessary, but we
have a lot of knowledge now and can begin to take action.
III. Tailored national screening and vaccination
programmes
In May 2010, the World Health Assembly recognized viral
hepatitis, and in particular hepatitis B and C, as a global
public health problem. This Summit Conference is a recog-
nition, by the EU public health community, of the need for
European-level action against viral hepatitis.
What needs to be done in Europe? This is where finding
conclusions becomes a bit more difficult because the ECDCs
technical reports show that the epidemiology of hepatitis B
and C in Europe is very diverse. For example, some countries
have significant levels of infection among the general pop-
ulation; in others, however, hepatitis B and C are rare
among the general population. Their epidemics are con-
centrated in groups at risk, such as migrants from high-
epidemic countries and injecting drug-users.
From data we already have, it is evident that this is not an
epidemic for which the EU can devise a one-size-fits-all
solution. We need solutions that are tailored to the reality of
the local and national situation in European countries. More
data are needed to allow us to do this tailoring, but be
careful, because we have a lot of information. More preva-
lence surveys are needed, especially in sub-populations, and
improved reporting of case-based surveillance, so that a
fuller picture of the epidemics becomes available. In high-
prevalence countries, universal screening and vaccination
programmes might be cost-effective, if the price of test kits
and vaccines is low. This is much less likely to be the case in
lower-prevalence countries such as Germany, the Nether-
lands or the UK. In these countries, though, screening of
certain high-prevalence populations such as migrants or
IDUs could be cost-effective.
I am a doctor but as a public health official, I am obliged to
call for evidence-informed decisions on screening and vacci-
nation programmes which look at costs as well as, of course,
the benefits. The Europe-wide evidence indicates that screen-
ing and vaccination programmes in Europe need to be tailored
to suit different national epidemics. The challenge for the
ECDC and the EU is to manage this huge diversity in Europe.
IV. Managing diversity – not tolerating unjustified
inequalities
Managing diversity should not mean tolerating unjustified
inequalities. I call on you to read the report, in which you
will find a lot of evidence. Use that evidence in your coun-
tries, and have your policymakers use it. We are not able to
sign the Call to Action because of reasons which I think you
understand, but please use the data.
In terms of unjustified inequalities, some national differ-
ences came to light during the compilation of the ECDCs
technical reports which are very difficult to justify or to ac-
cept. The most striking example is the fact that a few
countries appear not to offer hepatitis B testing to pregnant
women. This means that the opportunity to prevent mother-
to-child transmission is lost.
I hope that, in the EU, we can at least aspire to prevention
for all. Antenatal testing for hepatitis B is a very cost-effec-
tive prevention measure that should be implemented across
the whole of Europe. I hope that EU solidarity means that
better-resourced countries will help their poorer or less well-
organized counterparts to achieve this. Rather than just
talking, please act.
The EU, and particularly ECDC, has an important role to
play in identifying and sharing good practice in the pre-
vention and control of hepatitis B and C. Health interest
groups and professional associations, such as the organizers
of this Conference, can also make a major contribution to
sharing and disseminating knowledge. By sharing this
knowledge and working together to identify good practice,
we can facilitate a levelling upward of hepatitis B and C
prevention and control in Europe.
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V. Conclusions
My conclusions are:
Hepatitis B and C are extremely serious public health
problems.
We have enough evidence already to know that we need
to act.
Screening and vaccination programmes are part of the
answer, but must be tailored to suit different national epi-
demics.
Europes health experts must work together and pool their
knowledge on hepatitis B and C.
ANNEX II: CALL TO ACTION OF THE HEPATITIS B
AND C SUMMIT CONFERENCE
October 15th, 2010
This Call to Action is endorsed by:
Alojz Peterle MEP
Viral Hepatitis Prevention Board
European Monitoring Centre for Drugs and Drug Addiction
European Association for the Study of the Liver
European Liver Patients Association
World Hepatitis Alliance
International Centre for Health, Migration and Development.
The Hepatitis B and Hepatitis C Summit Conference brings
together a wide range of stakeholders united in their goal to
encourage European and national leaders to devise effective
policies and implement-targeted actions to curb the occur-
rence of hepatitis B and C in Europe. The Conference com-
mends previous work in the domain of hepatitis B and C and
aims to build on these initiatives, in particular the 63rd
World Health Assemblys resolution on Viral Hepatitis of
May 2010, MEP Thomas Ulmers Call to Action on Hepatitis
B launched at the European Parliament in 2006 and the
European Parliaments Written Declaration on Hepatitis C in
2007.1
The Steering Group of the Hepatitis B and Hepatitis C
Summit Conference, together with its partner associations,
calls on the EU Member States and the European Commis-
sion to:
1 Improve awareness of the threat posed by Hepatitis B and
Hepatitis C
2 Integrate prevention programmes for Hepatitis B and
Hepatitis C into existing public health frameworks
3 Enhance surveillance for Hepatitis B and Hepatitis C
across Europe
4 Support the development and integration of cost-effective
technologies and procedures for use in viral hepatitis
prevention, control and management, including screen-
ing of high risk individuals according to scientific and
epidemiological based evidence
5 Ensure universal access to early counselling and treat-
ment for persons infected with hepatitis B or hepatitis C
6 Expand research resources for hepatitis B and hepatitis C.
Improve awareness of the threat posed by hepatitis B and
hepatitis C
1 The message that hepatitis B and C pose a significant
threat to public health and are the leading cause of liver
cancer must be continually reinforced to policymakers
and to the general public.
2 Innovative and sensitive public health campaigns are
needed to ensure that individuals are made aware of the
risks of hepatitis B and C infection and transmission. At
the same time, care should be taken to de-stigmatize viral
hepatitis and encourage the social integration of people
infected with hepatitis B and C.
Integrate prevention programmes for hepatitis B and
hepatitis C into existing public health frameworks
1 Vaccination programmes against hepatitis B should be
integrated into routine health programmes in order to
reach as many individuals as possible.
2 At the same time, existing vaccination policies against
hepatitis B should be reassessed to ensure that they
1Of particular note are:
• The 63rd World Health Assembly Resolution on Viral Hepatitis, adopted on 21 May 2010;
• MEP Thomas Ulmers Call to Action on Hepatitis B launched at the European Parliament in 2006, and the European
Parliaments Written Declaration on Hepatitis C requesting ia. a Council Recommendation to promote screening for Hep-
atitis;
• The European Parliament Report of April 2010 on the European Commissions Communication on Action Against Cancer,
which Urges that... the prevention and control of diseases which can develop into cancer, for instance primary and
secondary prevention of viral hepatitis and treatment where appropriate, should be addressed by the Cancer Partnership and
in future EU initiatives, such as a revised Council recommendation on cancer screening;
• The inclusion of Hepatitis B and C in the surveillance and monitoring programmes of the European Centre for Disease
Prevention and Control (ECDC) and the EMCDDA;
• Work currently undertaken by the European Association for Disease of the Liver (EASL), the European Liver Patient
Association (ELPA), and the VHPB.
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reflect current epidemiology and reach at-risk target
groups.
3 Beside universal hepatitis B vaccination programmes
aimed at reaching newborn, infants, and/or children,
critical target groups include: household contacts of
people infected with HBV, migrants, IDUs, prisoners,
health care workers, blood donors, pregnant women and
newborns and people infected with HIV.
4 Hepatitis C testing and treatment of IDUs, among whom
most current hepatitis C transmission is occurring,
should be considered a public health imperative and fully
integrated into national substance misuse programmes.
Enhance surveillance for hepatitis B and hepatitis C across
Europe
1 Comprehensive and enhanced surveillance of hepatitis B
and C should be developed and implemented at the EU-
level under the coordination of the European Centre for
Disease Prevention and Control.
2 National protocols for disease surveillance must be
harmonized with the EU framework for hepatitis B and
C surveillance, which may include chronic cases of
hepatitis B and C in order to convey the full burden that
they pose.
Support the development and integration of cost-effective
technologies and procedures for use in viral hepatitis
prevention, control and management, including screening
of high risk individuals according to scientific and
epidemiological based evidence
1 Strengthen health systems in order to adequately provide
local populations with the most cost-effective and afford-
able interventions in accordance with the local epidemi-
ological situations.
2 Screening of high risk individuals should be prioritized.
Legal and ethical implications should be always consid-
ered.
Ensure universal access to early counselling and treatment
for persons infected with hepatitis B or hepatitis C
1 Currently available treatments are potentially curative,
reducing mortality from cirrhosis and liver cancer.
2 Universal and equal access to hepatitis B and hepatitis C
counselling and possible therapy must be considered a
priority across Europe for their public health impact to be
reduced.
3 Leadership from national governments is necessary to
dispel the myth that hepatitis B and C are untreatable,
and to actively promote the availability and early use
of effective treatments for affected individuals in
accordance with European guidelines and treatment
protocols.
Expand research resources for hepatitis B and hepatitis C
1 National and EU-level research funding organizations are
urged to allocate explicit funds towards research on the
epidemiology, prevention and treatment of hepatitis B
and C.
2 Liver disease, including hepatitis B and C, should become
a priority area for future research within the seventh
and eighth Research Framework Programmes of the EU.
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